Buckingham Capital Management Inc. Has $1.37 Million Position in Gilead Sciences, Inc. (GILD)
Buckingham Capital Management Inc. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,284 shares of the biopharmaceutical company’s stock after selling 255 shares during the quarter. Buckingham Capital Management Inc.’s holdings in Gilead Sciences were worth $1,365,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. Keel Point LLC boosted its position in Gilead Sciences by 0.4% during the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 11 shares during the period. West Oak Capital LLC boosted its position in Gilead Sciences by 0.7% during the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after acquiring an additional 32 shares during the period. First Heartland Consultants Inc. boosted its position in Gilead Sciences by 0.4% during the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after acquiring an additional 39 shares during the period. Arrow Financial Corp boosted its position in Gilead Sciences by 0.3% during the 2nd quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock worth $1,258,000 after acquiring an additional 45 shares during the period. Finally, Westover Capital Advisors LLC boosted its position in Gilead Sciences by 0.8% during the 1st quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after acquiring an additional 46 shares during the period. Institutional investors and hedge funds own 76.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $72.44 on Monday. The stock has a market capitalization of $94,626.13, a PE ratio of 7.56, a PEG ratio of -1.21 and a beta of 1.13. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s revenue was down 13.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.75 EPS. research analysts expect that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.69%.
A number of research analysts have issued reports on the company. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Deutsche Bank AG reissued a “buy” rating and issued a $81.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Mizuho reissued a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Leerink Swann reissued a “hold” rating and issued a $74.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 25th. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $84.87.
TRADEMARK VIOLATION NOTICE: This article was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/buckingham-capital-management-inc-has-1-37-million-position-in-gilead-sciences-inc-gild/1715068.html.
In related news, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 50,000 shares of the stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the sale, the executive vice president now owns 113,237 shares of the company’s stock, valued at approximately $8,945,723. The disclosure for this sale can be found here. In the last quarter, insiders have sold 666,819 shares of company stock valued at $52,303,086. 1.30% of the stock is currently owned by corporate insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.